Comment by s1artibartfast

This is a pretty outdated view, particularly with respect to biologics, which are some of the most complex structures humans fabricate. Many are in fact quite similar to iterative prototypes of jet engines.

You might have something like Anti–vascular endothelial growth factor therapy, where you have a binding target structure, and iterate the uses and molecular structure around it, or combine it with other structures and binding sites.

You might go from mab to fab, or to bispecific mab using CrossMab IgG architecture, or bispecific fab using dutafab fragment architechture. This analogizes to mixing and matching different jet engine technologies into different platofrms.

VEGF targeting biologics have netted >150 billion dollars to date, and this will only grow faster in the future.

iterative GLP-1 technologies will be much the same, where people are literally iteratively fixing bugs.

The development pipeline for both is littred with failed iterations.